- Home
- WRAP vs ACET Comparison
WRAP vs ACET Comparison
Compare WRAP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- ACET
- Stock Information
- Founded
- WRAP 2016
- ACET 1947
- Country
- WRAP United States
- ACET United States
- Employees
- WRAP N/A
- ACET N/A
- Industry
- WRAP Ordnance And Accessories
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- ACET Health Care
- Exchange
- WRAP Nasdaq
- ACET Nasdaq
- Market Cap
- WRAP 82.1M
- ACET 93.1M
- IPO Year
- WRAP N/A
- ACET N/A
- Fundamental
- Price
- WRAP $1.62
- ACET $0.91
- Analyst Decision
- WRAP
- ACET Strong Buy
- Analyst Count
- WRAP 0
- ACET 4
- Target Price
- WRAP N/A
- ACET $5.67
- AVG Volume (30 Days)
- WRAP 251.1K
- ACET 776.5K
- Earning Date
- WRAP 11-14-2024
- ACET 11-06-2024
- Dividend Yield
- WRAP N/A
- ACET N/A
- EPS Growth
- WRAP N/A
- ACET N/A
- EPS
- WRAP N/A
- ACET N/A
- Revenue
- WRAP $4,231,000.00
- ACET N/A
- Revenue This Year
- WRAP N/A
- ACET N/A
- Revenue Next Year
- WRAP N/A
- ACET N/A
- P/E Ratio
- WRAP N/A
- ACET N/A
- Revenue Growth
- WRAP N/A
- ACET N/A
- 52 Week Low
- WRAP $1.21
- ACET $0.81
- 52 Week High
- WRAP $7.01
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- WRAP 46.24
- ACET 37.30
- Support Level
- WRAP $1.53
- ACET $0.81
- Resistance Level
- WRAP $1.79
- ACET $0.98
- Average True Range (ATR)
- WRAP 0.12
- ACET 0.08
- MACD
- WRAP -0.03
- ACET -0.00
- Stochastic Oscillator
- WRAP 23.08
- ACET 31.25
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc offers public safety technologies and services. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.